Skip to main content
SpringerLink
Log in

Onkologische Immuntherapie und mögliche endokrine Nebenwirkungen bei Frauen

Oncological immunotherapy and possible endocrine side effects in women

  • Menopause und Frauengesundheit
  • Published:
Gynäkologische Endokrinologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Kuru S, Khan N, Shaaban H (2017) Acute hypophysitis secondary to nivolumab immunotherapy in a patient with metastatic melanoma. Int J Crit Illn Inj Sci 7(3):177–180

    Article  PubMed  PubMed Central  Google Scholar 

  2. Puzanov I et al (2017) Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (SITC) toxicity management working group. J Immunother Cancer 5(1):95. https://doi.org/10.1186/s40425-017-0300-z.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. González-Rodríguez E, Rodríguez-Abreu D (2016) Immune checkpoint inhibitors: review and management of endocrine adverse events. Oncologist 21(7):804–816. https://doi.org/10.1634/theoncologist.2015-0509

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA (2014) Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer 21(2):371–381. https://doi.org/10.1530/ERC-13-0499

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Min L, Hodi FS (2014) Anti-PD1 following Ipilimumab for Mucosal melanoma: durable tumor response associated with severe hypothyroidism and Rhabdomyolysis. Cancer Immunol Res 2(1):15–18. https://doi.org/10.1158/2326-6066.CIR-13-0146

    Article  PubMed  Google Scholar 

  6. Zeng MF et al (2017) Primary hypothyroidism and isolated ACTH deficiency induced by nivolumab therapy: case report and review. Medicine (Baltimore) 96(44):e8426. https://doi.org/10.1097/MD.0000000000008426

    Article  Google Scholar 

  7. Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS (2016) Nivolumab in resected and unresectable metastatic melanoma: Characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 22(4):886–894. https://doi.org/10.1158/1078-0432.CCR-15-1136

    Article  CAS  PubMed  Google Scholar 

  8. Schadendorf D et al (2017) Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with Nivolumab and Ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J Clin Oncol 35(34):3807–3814

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Angell TE, Min L, Wieczorek TJ, Hodi FS (2018) Unique cytologic features of thyroiditis caused by immune checkpoint inhibitor therapy for malignant melanoma. Genes Dis 5(1):46–48. https://doi.org/10.1016/j.gendis.2017.11.002

    Article  CAS  PubMed  Google Scholar 

  10. Ariyasu H et al (2018) Thyrotoxicosis and adrenocortical hormone deficiency during immune-checkpoint inhibitor treatment for malignant melanoma. In Vivo 32(2):345–351

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Min L, Vaidya A, Becker C (2011) Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol 164(2):303–307. https://doi.org/10.1530/EJE-10-0833

    Article  CAS  PubMed  Google Scholar 

  12. de Filette J et al (2016) Incidence of thyroid-related adverse events in melanoma patients treated with Pembrolizumab. J Clin Endocrinol Metab 101(11):4431–4439

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Osorio JC et al (2017) Antibody-mediated thyroid dysfunction during T‑cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol 28(3):583–589. https://doi.org/10.1093/annonc/mdw640

    Article  CAS  PubMed  Google Scholar 

  14. Guaraldi F et al (2018) Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution. J Endocrinol Invest 41(5):549–556. https://doi.org/10.1007/s40618-017-0772-1

    Article  CAS  PubMed  Google Scholar 

  15. Delivanis DA et al (2017) Pembrolizumab-induced Thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms. J Clin Endocrinol Metab 102(8):2770–2780

    Article  PubMed  PubMed Central  Google Scholar 

  16. Akarca FK, Can O, Yalcinli S, Altunci YA (2017) Nivolumab, a new immunomodulatory drug, a new adverse effect; adrenal crisis. Turkish J Emerg Med 17(4):157–159. https://doi.org/10.1016/j.tjem.2017.05.007

    Article  Google Scholar 

  17. Walter JR, Xu S, Paller AS, Choi JN, Woodruff TK (2016) Oncofertility considerations in adolescents and young adults given a diagnosis of melanoma: fertility risk of food and drug administration-approved systemic therapies. J Am Acad Dermatol 75(3):528–534

    Article  PubMed  PubMed Central  Google Scholar 

  18. Grunewald S, Jank A (2015) New systemic agents in dermatology with respect to fertility, pregnancy, and lactation. Jddg J Dtsch Dermatologischen Ges 13(4):277–290

    Google Scholar 

  19. Zamah AM et al (2011) Will imatinib compromise reproductive capacity? Oncologist 16(10):1422–1427

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Münster, Albert-Schweitzer-Str. 33, 48149, Münster, Deutschland

    Kristina Zdanyte &  Ludwig Kiesel

Authors
  1. Kristina Zdanyte
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ludwig Kiesel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kristina Zdanyte.

Ethics declarations

Interessenkonflikt

K. Zdanyte und L. Kiesel geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

Redaktion

L. Kiesel, Münster

A.O. Mueck, Tübingen

P. Stute, Bern

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zdanyte, K., Kiesel, L. Onkologische Immuntherapie und mögliche endokrine Nebenwirkungen bei Frauen. Gynäkologische Endokrinologie 17, 185–188 (2019). https://doi.org/10.1007/s10304-019-0255-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10304-019-0255-x

Search

Navigation